Free Trial
→ $2 Trillion Disappears Because of Fed's Secretive New Move (From Stansberry Research) (Ad)

Ainos Q1 2023 Earnings Report

Ainos logo
$0.62 -0.01 (-1.68%)
As of 03:58 PM Eastern
Earnings History

Ainos EPS Results

Actual EPS
-$0.65
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ainos Revenue Results

Actual Revenue
$0.05 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ainos Announcement Details

Quarter
Q1 2023
Date
5/12/2023
Time
N/A

Conference Call Resources

Ainos Earnings Headlines

Ainos granted 180-day extension to regain Nasdaq compliance
January 18 at 12:01 PM | markets.businessinsider.com
Ainos, Inc. (NASDAQ:AIMD) Short Interest Down 30.8% in December
January 16, 2025 | americanbankingnews.com
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
January 21, 2025 | Stansberry Research (Ad)
Ainos, Inc. Reports Q3 Financial Results and Strategic Developments
November 25, 2024 | tipranks.com
Ainos announces IRB approval for Sjogren’s Syndrome clinical study
November 11, 2024 | markets.businessinsider.com
Ainos files complaints over concerns about unsual trading activity
November 8, 2024 | markets.businessinsider.com
See More Ainos Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ainos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ainos and other key companies, straight to your email.

About Ainos

Ainos (NASDAQ:AIMD), a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

View Ainos Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles